Psychedelic-medicine stocks dropped sharply early Wednesday, a day after an independent panel of Food and Drug Administration advisers said the benefits of a MDMA-assisted therapy for post-traumatic stress disorder do not outweigh its risks.
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnPsychedelic-medicine stocks dropped sharply early Wednesday, a day after an independent panel of Food and Drug Administration advisers said the benefits of a MDMA-assisted therapy for post-traumatic stress disorder do not outweigh its risks.nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]